[go: up one dir, main page]

CA2064815A1 - Composes heterocycliques therapeutiques - Google Patents

Composes heterocycliques therapeutiques

Info

Publication number
CA2064815A1
CA2064815A1 CA2064815A CA2064815A CA2064815A1 CA 2064815 A1 CA2064815 A1 CA 2064815A1 CA 2064815 A CA2064815 A CA 2064815A CA 2064815 A CA2064815 A CA 2064815A CA 2064815 A1 CA2064815 A1 CA 2064815A1
Authority
CA
Canada
Prior art keywords
formula
alkyl
hydrogen
heterocyclic compounds
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2064815A
Other languages
English (en)
Other versions
CA2064815C (fr
Inventor
Alan Duncan Robertson
Alan Peter Hill
Robert Charles Glen
Graeme Richard Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26297174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2064815(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909012672A external-priority patent/GB9012672D0/en
Priority claimed from GB919102182A external-priority patent/GB9102182D0/en
Application filed by Individual filed Critical Individual
Priority to CA002282890A priority Critical patent/CA2282890C/fr
Publication of CA2064815A1 publication Critical patent/CA2064815A1/fr
Application granted granted Critical
Publication of CA2064815C publication Critical patent/CA2064815C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Cephalosporin Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La présente invention se rapporte à des composés de formule (I) où n représente un nombre entier de 0 à 3; W représente un groupe de formule (i), (ii) ou (iii), où R représente hydrogène ou alkyle C1-4, X représente -O-, -S-, -NH-, ou -CH2-, Y représente oxygène ou soufre et le centre chiral (*) dans la formule (i) ou (ii) est dans sa forme (S) ou (R) ou représente un mélange de ceux-ci dans n'importe quelles proportions; et Z représente un groupe de formule (iv), (v) ou (vi) où R1 et R2 sont indépendamment sélectionnés à partir d'hydrogène et d'alkyle C1-4 et R3 représente hydrogène ou alkyle C1-4. L'invention décrit aussi des sels, des solvates et des dérivés physiologiquement fonctionnels de ces composés, ainsi que des procédés relatifs à leur préparation, des médicaments qui les contiennent et leur utilisation comme agents thérapeutiques, en particulier dans la prophylaxie et le traitement de la migraine.
CA002064815A 1990-06-07 1991-06-06 Composes heterocycliques therapeutiques Expired - Lifetime CA2064815C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002282890A CA2282890C (fr) 1990-06-07 1991-06-06 Composes heterocycliques therapeutiques

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB909012672A GB9012672D0 (en) 1990-06-07 1990-06-07 Therapeutic heterocyclic compounds
GB9012672.3 1990-06-07
GB9102182.4 1991-02-01
GB919102182A GB9102182D0 (en) 1991-02-01 1991-02-01 Therapeutic heterocyclic compounds
PCT/GB1991/000908 WO1991018897A1 (fr) 1990-06-07 1991-06-06 Composes heterocycliques therapeutiques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002282890A Division CA2282890C (fr) 1990-06-07 1991-06-06 Composes heterocycliques therapeutiques

Publications (2)

Publication Number Publication Date
CA2064815A1 true CA2064815A1 (fr) 1991-12-08
CA2064815C CA2064815C (fr) 1999-11-16

Family

ID=26297174

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002064815A Expired - Lifetime CA2064815C (fr) 1990-06-07 1991-06-06 Composes heterocycliques therapeutiques
CA002282890A Expired - Lifetime CA2282890C (fr) 1990-06-07 1991-06-06 Composes heterocycliques therapeutiques

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002282890A Expired - Lifetime CA2282890C (fr) 1990-06-07 1991-06-06 Composes heterocycliques therapeutiques

Country Status (37)

Country Link
US (3) US5399574A (fr)
EP (2) EP0636623B1 (fr)
JP (1) JP2738461B2 (fr)
KR (1) KR100215627B1 (fr)
AT (2) ATE204275T1 (fr)
AU (1) AU646871B2 (fr)
CA (2) CA2064815C (fr)
CZ (1) CZ288351B6 (fr)
DE (3) DE19775091I2 (fr)
DK (1) DK0486666T3 (fr)
EG (1) EG19650A (fr)
ES (1) ES2104708T3 (fr)
FI (3) FI105686B (fr)
GR (1) GR3024828T3 (fr)
HK (1) HK1000534A1 (fr)
HR (1) HRP940524B1 (fr)
HU (2) HU219974B (fr)
IE (1) IE911931A1 (fr)
IL (3) IL114690A (fr)
LT (1) LT3264B (fr)
LU (1) LU90205I2 (fr)
LV (1) LV10274B (fr)
MC (1) MC2210A1 (fr)
MX (1) MX9203421A (fr)
MY (1) MY110226A (fr)
NL (1) NL980001I2 (fr)
NO (2) NO300634B1 (fr)
NZ (1) NZ238424A (fr)
PL (1) PL166214B1 (fr)
PT (1) PT97888B (fr)
RU (1) RU2160736C2 (fr)
SA (1) SA05260104B1 (fr)
SI (2) SI21560B (fr)
SK (1) SK281621B6 (fr)
UA (1) UA37178C2 (fr)
WO (1) WO1991018897A1 (fr)
YU (1) YU48855B (fr)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
TW263508B (fr) * 1991-02-12 1995-11-21 Pfizer
US5639752A (en) * 1991-11-25 1997-06-17 Pfizer Inc Indole derivatives
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
TW288010B (fr) * 1992-03-05 1996-10-11 Pfizer
US5510362A (en) * 1992-03-13 1996-04-23 Merck, Sharp And Dohme Limited Imidazole, triazole and tetrazole derivatives
GB9207396D0 (en) * 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
KR0179072B1 (ko) * 1992-04-07 1999-03-20 알렌 제이. 스피겔 5-ht1 작동약으로서의 인돌 유도체
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
CA2132706C (fr) * 1992-04-10 1998-08-04 John Eugene Macor Derives de l'acylamino-indole, agonistes de 5-ht1
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9208463D0 (en) * 1992-04-16 1992-06-03 Merck Sharp & Dohme Therapeutic agents
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
US5567726A (en) * 1992-07-24 1996-10-22 Merck, Sharp & Dohme Ltd. Imidazole, Triazole and tetrazole derivatives
GB9216009D0 (en) * 1992-07-28 1992-09-09 Almirall Lab New indol derivatives
IL106445A (en) * 1992-07-30 1998-01-04 Merck Sharp & Dohme History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them
ES2056025B1 (es) * 1992-10-08 1995-05-01 Almirall Lab Nuevos derivados de indol.
TW251284B (fr) * 1992-11-02 1995-07-11 Pfizer
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
CZ59996A3 (en) * 1993-08-31 1996-06-12 Pfizer 5-arylindole derivatives per se and for treating diseases, intermediates for their preparation and pharmaceutical compositions based thereon
US6423731B2 (en) 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
JPH10501212A (ja) * 1994-05-19 1998-02-03 メルク シヤープ エンド ドーム リミテツド ５−ｈｔ▲下１ｄ▼−アルファ作働薬としてのインドール−３−イルアルキルのピペラジン、ピペリジンおよびテトラヒドロピリジン誘導体
PT765322E (pt) * 1994-06-01 2002-01-30 Astrazeneca Ab Derivados indole pro-farmacos de agonistas de receptores tipo 5-ht1
MX9700693A (es) * 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
GB9423682D0 (en) * 1994-11-23 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
CA2207201A1 (fr) * 1994-12-06 1996-06-13 Caroline Henry Derives de l'azetidine, de la pyrrolidine et de la piperidine utilises comme agonistes des recepteurs 5-ht1
DE4443892A1 (de) * 1994-12-09 1996-06-13 Bayer Ag 4-(Chinolin-2-yl-methoxy)-phenyl-essigsäurederivate
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
NZ305166A (en) * 1995-03-20 1998-12-23 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
GB9515060D0 (en) * 1995-07-22 1995-09-20 Wellcome Found Therapeutic heterocyclic compounds
GB9515305D0 (en) * 1995-07-26 1995-09-20 Wellcome Found Therapeutic heterocyclic compounds
GB9516143D0 (en) 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
US6909005B1 (en) 1995-08-07 2005-06-21 Astrazeneca Uk Limited One post synthesis of 2-oxazolidinone derivatives
GB9516145D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
WO1997013512A1 (fr) * 1995-10-10 1997-04-17 Eli Lilly And Company Les n-[2-substitue-3-(-aminoethyl)-1h-indol-5-yl] - amides: de nouveaux agonistes 5-ht¿1f?
WO1997016446A1 (fr) * 1995-11-02 1997-05-09 Merck Sharp & Dohme Limited Heteroaryle-alkylene-(homo)piperazinones bicycliques et leurs analogues thiones, leur preparation et leur utilisation en tant qu'agonistes selectifs de recepteurs de type 5-ht1
GB9609374D0 (en) * 1996-05-03 1996-07-10 Merck Sharp & Dohme Therapeutic agents
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6346625B1 (en) * 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
JP2004517081A (ja) * 2000-11-29 2004-06-10 イーライ・リリー・アンド・カンパニー １−（２−ｍ−メタンスルホンアミドフェニルエチル）−４−（ｍ−トリフルオロメチルフェニル）ピペラジンならびにその医薬的に許容しうる塩および溶媒和物
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
EP1435945B1 (fr) * 2001-06-05 2008-08-13 Aung-din, Ronald Therapie antimigraineuse par voie topique
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
EP2316469A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
EP1537113B9 (fr) 2002-06-21 2010-05-26 Suven Life Sciences Limited Arylalkyl indoles a affinite de recepteur de la serotonine utilises comme agents therapeutiques, leur procede de preparation et compositions pharmaceutiques contenant lesdits indoles
RU2340619C2 (ru) 2002-06-21 2008-12-10 Сувен Лайф Сайенсиз Лимитед Новые тетрациклические арилсульфонилиндолы с аффинностью к серотониновым рецепторам, пригодные в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции
ES2204302B2 (es) 2002-08-07 2005-03-01 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
ES2425143T3 (es) 2002-11-28 2013-10-11 Suven Life Sciences Limited N-Arilsulfonil-3-aminoalcoxiindoles
US7875605B2 (en) 2002-11-28 2011-01-25 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
KR100739987B1 (ko) 2002-12-18 2007-07-16 수벤 라이프 사이언시스 리미티드 세로토닌 수용체 친화력을 가지는 테트라사이클릭 3-치환인돌
WO2004056769A2 (fr) 2002-12-20 2004-07-08 Ciba Specialty Chemicals Holding Inc. Synthèse d'amines et intermédiaires pour cette synthèse
WO2004063175A1 (fr) * 2003-01-13 2004-07-29 Natco Pharma Limited Nouveau procede ameliore de preparation de (s)-4-(4-aminobenzyl)-2- oxazolidinone
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
US20040192958A1 (en) * 2003-03-25 2004-09-30 Hyatt John Anthony Process for preparing derivatives of 4-halobutyraldehyde
EP1625336B9 (fr) 2003-05-21 2012-03-21 Alexza Pharmaceuticals, Inc. Utilisation d'une couche de combustible solide, procédé pour fabriquer une telle couche et unité de chauffage correspondante
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
WO2004112723A2 (fr) * 2003-06-20 2004-12-29 Ronald Aung-Din Therapie locale pour le traitement des migraines, des claquages musculaires, des spasmes musculaires, de la spasticite et d'etats apparentes
HRP20090404T1 (hr) * 2003-07-24 2009-08-31 Euro-Celtique S.A. Spojevi piperidina i farmaceutski sastavi koji ih sadržavaju
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005075467A2 (fr) * 2004-02-06 2005-08-18 Ciba Specialty Chemicals Holding Inc. Formes cristallines de zolmitriptan
US7540286B2 (en) * 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
AU2004322756B2 (en) * 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US20060211751A1 (en) * 2004-11-19 2006-09-21 Reuven Izsak Zolmitriptan crystal forms
CN101247853B (zh) 2005-04-13 2014-11-12 轴突公司 具有nos抑制活性的取代的吲哚化合物
EP1981860B1 (fr) 2006-01-19 2011-05-25 Matrix Laboratories Ltd Conversion d'un sel de diazonium aromatique en arylhydrazine
ZA200809659B (en) 2006-04-13 2010-03-31 Neuraxon Inc 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity
WO2008018090A2 (fr) * 2006-08-09 2008-02-14 Matrix Laboratories Ltd Procédé de préparation amélioré de zolmitriptan
BRPI0715579A2 (pt) * 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
ES2691033T3 (es) * 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
CZ2007158A3 (cs) * 2007-02-26 2008-10-22 Zentiva, A. S. Zpusob prípravy zolmitriptanu
WO2008112661A2 (fr) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Unité chauffante à utiliser dans un dispositif d'administration de médicament
JP5372913B2 (ja) * 2007-04-27 2013-12-18 パーデュー、ファーマ、リミテッド、パートナーシップ 疼痛治療に有効な治療薬
ES2571533T3 (es) 2007-04-27 2016-05-25 Purdue Pharma Lp Antagonistas de TRPV1 y usos de los mismos
NZ584971A (en) * 2007-10-03 2012-06-29 Generics Uk Ltd Process for the preparation of zolmitriptan, salts and solvates thereof
EP2220074A4 (fr) * 2007-11-16 2012-01-04 Neuraxon Inc Composés d'indole 3,5-substitués ayant une activité d'inhibition de la réabsorption de la nos et de la noradrénaline
WO2009064505A1 (fr) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Procédés de traitement de la douleur viscérale
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
CN101181267B (zh) * 2007-11-30 2010-09-08 重庆医科大学医药研究所 佐米曲普坦舌下片
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
WO2010005507A1 (fr) 2008-06-30 2010-01-14 Afgin Pharma, Llc Traitement neuro-affectif régional topique
US20100217013A1 (en) * 2008-12-15 2010-08-26 Wenge Li Enantioselective process for the preparation of zolmitriptan
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
US20110038928A1 (en) * 2009-08-12 2011-02-17 Glenmark Generics Ltd Orally disintegrating tablets of zolmitriptan
HRP20161402T1 (hr) 2010-10-15 2016-12-30 Contera Pharma Aps Kombinacije agonista serotoninskih receptora za liječenje poremećaja kretanja
ES2620528T3 (es) 2011-06-22 2017-06-28 Purdue Pharma Lp Antagonistas de TRPV1 que incluyen un sustituyente dihidroxi y usos de los mismos
WO2013016223A2 (fr) 2011-07-22 2013-01-31 The University Of Chicago Traitements de la migraine et de troubles apparentés
WO2013057739A2 (fr) * 2011-09-02 2013-04-25 Emcure Pharmaceuticals Limited Procédé de préparation amélioré de zolmitriptan
MY169068A (en) 2012-04-18 2019-02-12 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
US9394314B2 (en) 2012-12-21 2016-07-19 Map Pharmaceuticals, Inc. 8′-hydroxy-dihydroergotamine compounds and compositions
EP3265081A4 (fr) 2015-03-02 2018-11-21 Afgin Pharma, Llc Thérapie neuro-affective régionale topique comprenant des cannabinoïdes
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
WO2017122161A1 (fr) 2016-01-15 2017-07-20 Cadila Healthcare Limited Composition intranasale comprenant des agonistes de récepteur 5ht1b/1d
US12194158B2 (en) 2016-01-27 2025-01-14 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
WO2018011181A1 (fr) 2016-07-11 2018-01-18 Contera Pharma Aps Système d'administration pulsatile de médicament pour le traitement de l'akinésie matinale
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
EP3746138B1 (fr) 2018-02-02 2025-12-10 Alexza Pharmaceuticals, Inc. Dispositif aérosol à condensation électrique
WO2020249802A1 (fr) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazolo-pyrazines substituées et leur utilisation en tant que modulateurs du récepteur de glun2b
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
EP3766483A1 (fr) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Composition de poudre orodispersible comprenant un triptane
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders
CN114394962A (zh) * 2021-12-22 2022-04-26 深圳市祥根生物医药有限公司 一种n-去甲基佐米曲普坦的制备方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB148879A (en) * 1919-02-14 1921-11-10 Emil Vincance Noser Locks for shift levers of automobiles
US3320282A (en) * 1962-10-29 1967-05-16 Pfizer & Co C Process for preparing esters of 2-hydroxy-3-(3-indolyl) alkanoic acids
US3879410A (en) * 1971-02-08 1975-04-22 Messrs Lab Guidotti & C S P A 4-Aryl-4-oxazolin-2-ones exhibiting myotonic and myorelaxing activity
BE795457A (fr) * 1972-02-16 1973-08-16 Clin Midy Amines indoliques, leur preparation et leur application en therapeutiques
FR2179582B1 (fr) * 1972-04-13 1975-10-10 Synthelabo
US3873559A (en) * 1973-03-30 1975-03-25 Squibb & Sons Inc Heterocyclic carboxamido thiazolinyl indoles
IT995110B (it) * 1973-08-01 1975-11-10 Snam Progetti Procedimento per la produzione di composti eterociclici e prodotti ottenuti
US4042595A (en) * 1973-08-01 1977-08-16 Snam Progetti S.P.A. Processes for the production of heterocyclic compounds
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4049816A (en) * 1975-03-24 1977-09-20 Beecham Group Limited Antiviral 2-amino-5-[1-(indol-3-yl)alkyl]-2-thiazolin-4-ones
FR2315925A1 (fr) * 1975-07-04 1977-01-28 Nippon Chemiphar Co Nouveaux derives de 5-benzyle-2-oxazolidone, leur procede de preparation et leur application en therapeutique
GB1482879A (en) * 1975-07-24 1977-08-17 Nippon Chemiphar Co 5-benzyl-2-oxazolidone derivatives and a process for producing the same
GB1469200A (en) * 1975-11-28 1977-03-30 Warner Lambert Co 3-thiomethyl-2-2-dialkylamino-ethyl-indoles
DE2557341A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
IT1109002B (it) * 1977-09-22 1985-12-16 Menarini Sas Derivati del 2 oxazolidone e loro metodi di preparazione
US4198501A (en) * 1977-12-20 1980-04-15 Hoffmann-La Roche Inc. Synthesis of tryptophans
US4137404A (en) * 1977-12-20 1979-01-30 Hoffmann-La Roche Inc. Synthesis of tryptophans
JPS6014032B2 (ja) * 1978-01-20 1985-04-11 日本ケミフア株式会社東京 ５‐フエネチル‐２‐オキサゾリドン誘導体およびその製法
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
DE2933636A1 (de) * 1978-08-30 1980-03-20 Sandoz Ag Neue n-phenylindolinderivate, ihre herstellung und pharmazeutische praeparate, welche diese verbindungen enthalten
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
DK151884C (da) * 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4272555A (en) * 1979-09-21 1981-06-09 Monsanto Company Conversion of carbon-containing materials to carbon monoxide
EP0083566A1 (fr) * 1980-04-10 1983-07-13 Sandoz Ag Isoxazolyl indoles
JPS574986A (en) * 1980-06-13 1982-01-11 Paamakemu Asia:Kk Preparation of oxazolidine derivative
US4367234A (en) * 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4753956A (en) * 1981-01-02 1988-06-28 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
NL8103769A (nl) * 1980-08-12 1982-03-01 Glaxo Group Ltd Heterocyclische verbindingen, werkwijze ter bereiding daarvan alsmede farmaceutische preparaten die deze verbindingen als actieve component bevatten.
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4407811A (en) * 1981-01-02 1983-10-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4399296A (en) * 1981-01-02 1983-08-16 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4448971A (en) * 1981-01-02 1984-05-15 Pfizer Inc. Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones
JPS57169458A (en) * 1981-04-13 1982-10-19 Paamakemu Asia:Kk Preparation of indole derivative
CH656124A5 (de) * 1982-04-13 1986-06-13 Sandoz Ag 2-substituierte-3-indolamine, verfahren zu deren herstellung sowie deren verwendung.
IT1170387B (it) * 1982-06-07 1987-06-03 Glaxo Group Ltd Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
US4500717A (en) * 1983-03-28 1985-02-19 The Dow Chemical Company Process for preparation of 2-oxazolidinones
US4831153A (en) * 1983-06-27 1989-05-16 The Dow Chemical Company Preparation of N-vinyl-2-oxazolidinone
GB8321813D0 (en) * 1983-08-12 1983-09-14 Vickers Plc Radiation sensitive compounds
DE3333450A1 (de) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt Trihalogenmethylgruppen enthaltende carbonylmethylenheterocyclen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindungen enthaelt
GB8332435D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
SE8505715L (sv) * 1984-12-04 1986-06-05 Glaxo Group Ltd Indolderivat
GB8431426D0 (en) * 1984-12-13 1985-01-23 Glaxo Group Ltd Chemical compounds
DE3514696A1 (de) * 1985-04-24 1986-11-06 Bayer Ag, 5090 Leverkusen N-indolylethyl-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung
DE3531658A1 (de) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
EP0225726B1 (fr) * 1985-11-08 1991-04-17 Glaxo Group Limited Dérivés de l'indole
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
SE451840B (sv) * 1986-01-03 1987-11-02 Astra Laekemedel Ab Optiskt rent monohydrat av s-(-)-1-propyl-2',6'-pipekoloxylididhydroklorid, sett att framstella denna och farmaceutiska beredningar for lokalbedovning
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8607824D0 (en) * 1986-03-27 1986-04-30 Glaxo Group Ltd Chemical compounds
DE3643957A1 (de) * 1986-12-22 1988-06-30 Bayer Ag Substituierte n-methylisoxazolidine
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
DE3882614T2 (de) * 1987-08-13 1993-11-18 Glaxo Group Ltd Indol-Derivate.
DE3730777A1 (de) * 1987-09-12 1989-03-23 Basf Ag Verfahren zur herstellung von imidazolidinonen und oxazolidinonen
US4801600A (en) * 1987-10-09 1989-01-31 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4965268A (en) * 1987-10-09 1990-10-23 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4921869A (en) * 1987-10-09 1990-05-01 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
DE3823299A1 (de) * 1988-07-07 1990-01-11 Schering Ag Substituierte phenyl-pyrrolidin-2-one, -oxazolidin-2-one und -imidazolidin-2-one, ihre herstellung sowie verwendung in arzneimitteln
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
EP0609905B1 (fr) * 1988-09-15 2001-06-06 PHARMACIA &amp; UPJOHN COMPANY 3-Phényl azoté-5-bêta-amidométhyl-oxazolidine-2-ones
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
DE3939238A1 (de) * 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
DE4013907A1 (de) * 1990-04-26 1991-10-31 Schering Ag Verfahren zur herstellung von gramin-derivaten
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
GB9104136D0 (en) * 1991-02-27 1991-04-17 Merck Sharp & Dohme Therapeutic agents
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives

Also Published As

Publication number Publication date
FI960155A7 (fi) 1996-01-12
PT97888B (pt) 1998-12-31
HU211479A9 (en) 1995-11-28
US5863935A (en) 1999-01-26
AU646871B2 (en) 1994-03-10
NO920494D0 (no) 1992-02-06
US5399574A (en) 1995-03-21
PT97888A (pt) 1992-05-29
IL114690A (en) 1997-02-18
JPH05502679A (ja) 1993-05-13
HUT62289A (en) 1993-04-28
KR920702359A (ko) 1992-09-03
DE69127260D1 (de) 1997-09-18
FI105686B (fi) 2000-09-29
EG19650A (en) 1995-09-30
SI9111010B (sl) 2005-02-28
NL980001I1 (nl) 1998-03-02
UA37178C2 (uk) 2001-05-15
CA2282890A1 (fr) 1991-12-08
YU101091A (sh) 1994-04-05
IL114690A0 (en) 1995-11-27
IL98392A0 (en) 1992-07-15
LT3264B (en) 1995-05-25
HRP940524A2 (en) 1996-06-30
YU48855B (sh) 2002-06-19
FI106262B (fi) 2000-12-29
HRP940524B1 (en) 1998-10-31
LV10274B (en) 1995-04-20
ATE204275T1 (de) 2001-09-15
ES2104708T3 (es) 1997-10-16
CA2064815C (fr) 1999-11-16
FI960155A0 (fi) 1996-01-12
HU9200384D0 (en) 1992-06-29
NO920494L (no) 1992-03-30
LU90205I2 (fr) 1998-04-06
KR100215627B1 (ko) 1999-08-16
PL166214B1 (pl) 1995-04-28
SA05260104B1 (ar) 2006-04-04
EP0486666A1 (fr) 1992-05-27
FI920503A0 (fi) 1992-02-06
IL98392A (en) 1996-01-19
MX9203421A (es) 1992-07-01
SI21560A (sl) 2005-02-28
NL980001I2 (nl) 1998-05-06
IE20010862A1 (en) 2003-03-05
RU2160736C2 (ru) 2000-12-20
DE19775091I2 (de) 2007-05-24
CA2282890C (fr) 2001-07-31
MC2210A1 (fr) 1992-11-26
DK0486666T3 (da) 1998-03-30
NO300634B1 (no) 1997-06-30
LTIP419A (en) 1994-11-25
DE69132691T2 (de) 2002-06-20
MY110226A (en) 1998-03-31
AU7957091A (en) 1991-12-31
DE69132691D1 (de) 2001-09-20
SA05260104A (ar) 2005-12-03
ATE156823T1 (de) 1997-08-15
NZ238424A (en) 1993-12-23
GR3024828T3 (en) 1998-01-30
SI9111010A (en) 1997-12-31
CZ288351B6 (en) 2001-05-16
SI21560B (sl) 2005-04-30
IE911931A1 (en) 1991-12-18
HK1000534A1 (en) 1998-04-03
EP0636623A1 (fr) 1995-02-01
LV10274A (lv) 1994-10-20
EP0636623B1 (fr) 2001-08-16
FI20001406A7 (fi) 2000-06-13
US5466699A (en) 1995-11-14
EP0486666B1 (fr) 1997-08-13
DE69127260T2 (de) 1997-12-04
CS172791A3 (en) 1992-02-19
SK281621B6 (sk) 2001-05-10
HU219974B (hu) 2001-10-28
JP2738461B2 (ja) 1998-04-08
NO1998005I1 (no) 1998-01-21
WO1991018897A1 (fr) 1991-12-12

Similar Documents

Publication Publication Date Title
CA2064815A1 (fr) Composes heterocycliques therapeutiques
IL88122A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing them
CA2256582A1 (fr) Acides oxa et composes apparentes utilises dans le traitement d&#39;etats dermatologiques
HU896769D0 (en) Fungicide compositions comprising azolylmethylcyclopentane-benzylidene-derivatives as active ingredient and process for preparation of the active ingredients
ATE60761T1 (de) Chinazolinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
TW377344B (en) Cyclobutyl substituted indole derivative, their preparation, pharmaceutical compositions containing them and their use in the prophylaxis and treatment of migraine
HUT43051A (en) Process for preparing pyridine-carboxylic acid derivatives and pharmaceutical compositions containing thereof as active ingredients
ES8503667A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-oxo-imidazolina.
PL309874A1 (en) Novel derivatives of pyrrolocarbasol, method of obtaining them and pharmaceutical composition containing such derivatives
ZA873884B (en) 2-thiazolyl imidazo(1,2-a)pyrimidines and their salts,their process of preparation,their application as medicaments and compositions containing them
IL93259A0 (en) Aryl derivatives,their preparation and pharmaceutical compositions containing them
ES8501410A1 (es) Un procedimiento para la preparacion de nuevos derivados de fosfolipidos.
HU9401161D0 (en) Oxazolidone derivatives, process for producing them and pharmaceutical compositions containing them
IL96618A0 (en) Pharmaceutical compositions containing fluoroquinolone derivatives
ZA912618B (en) 3-aminochroman derivatives,process for preparing these and pharmaceutical compositions containing them
IE893956L (en) Novel compounds
HU893127D0 (en) Process for the preparation of novel spiro-(imidazolidino-naphtaline) derivatives and pharmaceutical compositions containing such compounds as active ingredient
HUT41025A (en) Process for preparing octahydro-indolizine derivatives and pharmaceutical compositions containing such compounds as active ingredients
IL115085A0 (en) Bicyclic carboxamide derivatives their preparation and pharmaceutical compositions containing them
ZA872925B (en) Heterocyclic compounds

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry